FIELD: medicine.
SUBSTANCE: invention refers to medicine and can be used as a diagnostic technique for hepatic fibrosis in patients with non-alcoholic fatty liver disease with type 2 diabetes mellitus. Levels of haptoglobin, alpha2-macroglobulin and gamma-glutamyltransferase are determined. Presence and extent of hepatic fibrosis is calculated by formula.
EFFECT: invention provides more effective diagnosis of hepatic fibrosis.
1 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND TYPE 2 DIABETES MELLITUS | 2018 |
|
RU2706026C1 |
| METHOD OF TREATMENT HEPATIC CIRRHOSIS OF VARIOUS ETIOLOGY | 2015 |
|
RU2593007C1 |
| METHOD FOR PREDICTING SEVERE HEPATIC FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2021 |
|
RU2765847C1 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR HEPATIC STEATOSIS AND STEATOHEPATITIS | 2013 |
|
RU2545990C2 |
| METHOD FOR PREDICTING NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2021 |
|
RU2765848C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE | 2013 |
|
RU2537229C1 |
| DIAGNOSTIC TECHNIQUE FOR HEPATIC FIBROSIS ACCOMPANYING VIRAL HEPATITIS C | 2014 |
|
RU2557927C1 |
| DIAGNOSTIC TECHNIQUE FOR ASYMPTOMATIC CELIAC DISEASE IN ADULTS | 2020 |
|
RU2747523C1 |
| METHOD OF THE TREATMENT OF POLYNEUROPATHY ASSOCIATED WITH GLUTEN-SENSITIVE CELIAC DISEASE | 2022 |
|
RU2800847C1 |
| METHOD FOR DIAGNOSING SEVERE PSEUDOMEMBRANOUS COLITIS IN PATIENTS AFTER CORONAVIRUS INFECTION | 2022 |
|
RU2786752C1 |
